drugset / Trial / NCT05729386

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

NCT05729386

Phase 1 Unknown 34 enrolled GC Biopharma Corp
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of oral administration of GC2129A in fed conditions to healthy adult volunteers.

Timeline

Start
2023-02-06
Primary completion
2023-04-17
Completion
2023-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GC2129A Unknown Oral
Subject Linagliptin Small molecule 5 mg
Subject Metformin Small molecule 1000 mg

Indications

No indication recorded.